Neuropharmacology and potential efficacy of new treatments for tobacco dependence.
about
Nicotine receptor partial agonists for smoking cessationNicotine receptor partial agonists for smoking cessationNicotine vaccines for smoking cessationNicotine receptor partial agonists for smoking cessationCannabinoid type 1 receptor antagonists for smoking cessationNicotine vaccines for smoking cessationCognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder.Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.Anti-relapse medications: preclinical models for drug addiction treatment.Anxiolytics for smoking cessation.Nicotinic receptor antagonists as treatments for nicotine abuse.Treatment of tobacco dependence: integrating recent progress into practice.Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure.Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior.Synthesis and positron emission tomography studies of C-11-labeled isotopomers and metabolites of GTS-21, a partial alpha7 nicotinic cholinergic agonist drug.Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivityAddiction and brain reward and antireward pathways.Rimonabant for treating tobacco dependence.Oral varenicline for smoking cessation.Development of novel pharmacotherapeutics for tobacco dependence: progress and future directionsVarenicline for smoking cessation.Varenicline in the treatment of tobacco dependence.Pharmacotherapies for COPD.Current and emerging pharmacotherapeutic options for smoking cessation.Vaccination against nicotine: an emerging therapy for tobacco dependence.Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia.Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease.The endocannabinoid system: a new molecular target for the treatment of tobacco addiction.Smoking behaviour and mental health disorders--mutual influences and implications for therapyWhat do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?Nicotinic receptor-based therapeutics and candidates for smoking cessation.A review of smoking behavior and smokers evidence (chemical modification, inducing nicotine metabolism, and individual variations by genotype: dopaminergic function and personality traits).Emerging therapeutic targets for the treatment of nicotine addiction.Attenuation of cue-induced smoking urges and brain reward activity in smokers treated successfully with bupropion.Nicotinic Acetylcholine Receptors as Targets for Tobacco Cessation Therapeutics: Cutting-Edge Methodologies to Understand Receptor Assembly and Trafficking.
P2860
Q24185773-DB024295-1F76-4362-9BF8-0C0C9D7806A1Q24200322-C268D927-BFA4-4D98-BEFE-45414BB737CCQ24201422-3AE62BE7-0B71-488F-8090-6CBBF053DD76Q24235456-7AC2E02D-C8C1-424B-8CFB-31551EFB3D5BQ24235611-7560320E-0218-4659-8683-8D45BB5D3972Q24243661-2F79501A-9CAB-42E4-82FA-C023E9047EA4Q30396291-1013BE26-0959-4F23-BCA1-BC8703B113FAQ30497212-79A8BF0C-5B4F-4AA7-805D-46A1D9D81E44Q33870433-924916D0-87C5-4966-96A4-3F5B9A04E610Q33927470-EB0A2457-76AE-4453-BB80-3A6C87CAFE23Q34062467-4943EEAC-25AF-48BF-A3E6-F292E9BD28E8Q34401397-4721B053-E770-4BE8-87E0-42378D7EE109Q34715360-CC7F5483-9D94-4E45-B56E-BDF5BFEFA328Q35103785-0720D203-B598-4F73-9A8C-9686E8CBBE63Q35184641-F7D69008-CB9E-43E4-9B20-6AF72AC716E3Q35240381-99C0FEE3-B7A3-4902-91E4-DBF7DBA37C04Q35704853-05C85A60-4D21-48A3-99E7-F165757E21C2Q35995170-0615BE4E-D7B7-4ED4-A478-6FFE07329639Q36541435-E1DB673D-3F92-498F-8B57-5D1AF460A09DQ36693204-E9C0AE65-673F-40F4-96DF-D4B857041294Q36727844-4B31883C-07F8-4E46-8CA0-C9B56BB0B50DQ36730647-478A66E5-25C7-4340-A9AC-7AA8B7D96E6DQ36842193-8FD72332-1DDE-4C0E-821A-481E2FD7F69BQ36843717-8EAF8AE9-E647-4CD3-A3E9-64DB5A45C91CQ36891273-CC415709-6DE9-4DB2-AF45-28C59F6DE673Q36985864-2F2A3E00-2A30-4A5F-967A-03B211B89C52Q37079797-D8226BF5-4BD2-476D-B27E-B38B1A55A40BQ37197102-7ABE1AC7-1946-46F7-B30B-55ED677A2DC6Q37291517-1AB310B7-0FB3-41C8-888E-4ACCE32036B3Q37295878-7503A19F-7582-48E4-B9DC-D989AC3BF969Q37389475-65511957-4FF4-4885-964B-D5A9CBEF937AQ37518024-EAF2AFBC-ACA4-4533-A8EF-86AC94D5A52DQ37605893-657ADB86-25BA-40F9-948B-CFAF8ADE24B2Q38473341-6AD5CBC1-2EBD-4610-976C-473E5947955DQ43300290-50F79DAD-F866-464E-B844-DA61D069E349Q55085310-93280F23-4BEC-4964-9DE5-A74AD7FCAF04
P2860
Neuropharmacology and potential efficacy of new treatments for tobacco dependence.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Neuropharmacology and potential efficacy of new treatments for tobacco dependence.
@ast
Neuropharmacology and potential efficacy of new treatments for tobacco dependence.
@en
type
label
Neuropharmacology and potential efficacy of new treatments for tobacco dependence.
@ast
Neuropharmacology and potential efficacy of new treatments for tobacco dependence.
@en
prefLabel
Neuropharmacology and potential efficacy of new treatments for tobacco dependence.
@ast
Neuropharmacology and potential efficacy of new treatments for tobacco dependence.
@en
P2860
P1476
Neuropharmacology and potential efficacy of new treatments for tobacco dependence.
@en
P2093
David J K Balfour
Karl Fagerström
P2860
P304
P356
10.1517/13543784.15.2.107
P407
P577
2006-02-01T00:00:00Z